Garlic in Hyperlipidemia Caused by HAART
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to test the effectiveness and tolerability of garlic pills in lowering cholesterol and triglycerides in hyperlipidemic HIV-infected individuals who are being treated with highly active antiretroviral therapy (HAART).
| Condition | Intervention | Phase |
|---|---|---|
|
HIV Infections Hypercholesterolemia Hypertriglyceridemia Hyperglycemia |
Drug: Garlic powder standardized to allicin |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study on the Effects of Garlic on Hyperlipidemia Induced by HAART in HIV-Positive Individuals |
| Estimated Enrollment: | 146 |
| Study Start Date: | November 2001 |
Clinical evaluation of garlic in HIV disease is warranted for several reasons. First, garlic is used as a botanical medicine and as an alternative therapy by many HIV-infected individuals. Baseline data from the Bastyr's Alternative Medicine Care Outcomes in AIDS (AMCOA) study [1] indicate that garlic is the most frequently used botanical medicine among HIV-infected men and women (52.9%) who utilize complementary and alternative medicine (CAM). In the same cohort, 50% of the subjects who use antiretroviral therapy are also taking garlic supplements. Second, there is a growing body of studies that indicate that garlic exhibits lipid and glucose lowering as well as hepato-protective activities. Third, several of the pharmacological activities of garlic and their reported clinical benefits in other conditions, especially in hyperlipidemia, may be relevant in the management of highly active antiretroviral therapy (HAART) in HIV-infected subjects.
Study Medication: We will utilize GarlicinTM, an allicin-standardized dried garlic supplement in two escalating doses in HIV-infected subjects who are receiving HAART.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- HIV-1 seropositive confirmed by medical history
- On stable HAART for at least 6 months before study entry without the likelihood of HAART therapy changes in the following 6 months due to viral rebound or adverse events
- CD4+ lymphocyte number > 100 cells/mm3 measured within 60 days before study entry
- HIV-1 viral load < 2000 RNA copies/ml
- Cholesterol > 200 mg/dL
- Triglycerides > 250 mg/dL < 1000 mg/dL
- Willing and able to avoid raw or dry garlic, onion, leeks and shallots as well as supplements containing garlic during the 16 weeks of the trial
- Willing and able to provide inform consent
- Willing and able to understand and follow protocol for the duration of the study
- Willing and able to maintain a consistent lifestyle routine, eg. diet, exercise, medications, dietary supplements and sleep schedule for the duration of the study
- Willing and able to understand and follow the Step 1 guidelines from the National Cholesterol Education Program (NCEP) for the duration of the study
- Willing to remain adherent to the current HAART regimen
Contacts and Locations| United States, Washington | |
| Bastyr University Center for Natural Health | |
| Seattle, Washington, United States, 98103 | |
| University of Washington Harborview Medical Center | |
| Seattle, Washington, United States, 98104 | |
| Principal Investigator: | Leanna J Standish, ND, PhD | Bastyr University |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00029250 History of Changes |
| Other Study ID Numbers: | R21 AT000328-01 |
| Study First Received: | January 9, 2002 |
| Last Updated: | August 2, 2007 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Center for Complementary and Alternative Medicine (NCCAM):
|
complementary therapies garlic Allium sativum |
metabolic diseases HAART Protease inhibitors |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Hypercholesterolemia Hyperglycemia Hyperlipidemias Hypertriglyceridemia Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases |
Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases Glucose Metabolism Disorders Allicin Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Antioxidants Protective Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on March 03, 2013
